MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-09-2024
Alpine Immune Sciences Operating Cycle 2011-2026 | ALPN
Annual Operating Cycle Alpine Immune Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 154 | 195 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 195 | 154 | 174 |
Quarterly Operating Cycle Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.36 | - | 2.29 | 5.05 | 5.15 | - | 9.26 | 12.5 | 84.1 | - | 243 | 288 | - | - | 1.26 K | 315 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 K | 1.36 | 202 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
4.89 | $ 1.06 | -0.93 % | $ 5.78 M |  China |
 |
Adagene
ADAG
|
53.8 | $ 1.65 | - | $ 92.9 M | China |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 64.9 | -0.15 % | $ 8.68 B |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Biogen
BIIB
|
452 | $ 187.4 | 0.75 % | $ 27.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioXcel Therapeutics
BTAI
|
244 | $ 1.98 | -1.0 % | $ 5.02 M | USA |
 |
CASI Pharmaceuticals
CASI
|
135 | $ 1.04 | -2.34 % | $ 142 M | USA |
 |
Catalyst Biosciences
CBIO
|
410 | $ 10.74 | -2.1 % | $ 707 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 27.0 | -1.28 % | $ 1.74 M | USA |
 |
Cellectis S.A.
CLLS
|
136 | $ 4.42 | -1.34 % | $ 116 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
195 | $ 27.75 | 0.02 % | $ 1.34 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
408 | $ 11.13 | -2.02 % | $ 720 M | USA |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
Axon Enterprise
AXON
|
116 | $ 633.45 | 3.34 % | $ 48 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
360 | $ 2.64 | -0.75 % | $ 16.6 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AstraZeneca PLC
AZN
|
206 | $ 94.65 | 0.68 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |